Daptomycin resistant Enterococcus faecalis has a mutation in liaX, which encodes a surface protein that inhibits the LiaFSR systems and cell membrane remodeling

J Infect Chemother. 2021 Jan;27(1):90-93. doi: 10.1016/j.jiac.2020.09.004. Epub 2020 Sep 22.

Abstract

The emergence of daptomycin (DAP) resistant Enterococcus species has increased worldwide, but the mechanisms for DAP resistance are not fully understood. We report a case of DAP resistant Enterococcus faecalis, from a clinical sample of a patient with diabetic ulcers, after DAP therapy. Whole-genome sequencing analysis revealed that the isolate had a loss-of-function point mutation within liaX encoding DAP-sensing surface protein, which inhibits the LiaFSR systems and cell membrane remodeling. This is the first case report of a clinical DAP resistant E. faecalis with a mutation in liaX.

Keywords: Daptomycin; Enterococcus faecalis; LiaX; Whole-genome sequencing.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Proteins / genetics
  • Cell Membrane
  • Daptomycin* / pharmacology
  • Daptomycin* / therapeutic use
  • Drug Resistance, Bacterial / genetics
  • Enterococcus faecalis / genetics
  • Humans
  • Membrane Proteins
  • Microbial Sensitivity Tests
  • Mutation / genetics

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Membrane Proteins
  • Daptomycin